Streetbeat News

Earnings

VZIO

WMT

Telsey Advisory Group analyst Joseph Feldman upgraded Walmart Inc. (WMT) to an Outperform rating with a target price of $205, up from $185, citing Walmart's expanded vision beyond retail into advertising, merchant services, and last-mile delivery. Walmart's Q4 FY24 net sales grew by 5.7% to $173.39 billion, surpassing expectations. Adjusted EPS was $1.80, beating the consensus of $1.65. The company's international division saw a 17.6% sales increase, with significant growth in Flipkart and China. Walmart also agreed to acquire VIZIO Holding Corp. (VZIO) for $2.3 billion, a move expected to bolster its advertising growth but be dilutive to 2024 earnings. Feldman maintains a 2024 EPS estimate of $7.13 with a projected total sales growth of 4% to $674 billion.

Portfolio Pulse from Nabaparna Bhattacharya

February 21, 2024 | 7:01 pm

ONTF

ON24 (NYSE:ONTF) is scheduled to release its quarterly earnings report on February 22, 2024, with analysts estimating an EPS of $0.01. The company's past earnings performance shows a mixed record of beating and missing EPS estimates, with share price reactions varying accordingly. Shares of ON24 were trading at $8.05 as of February 20, 2024, reflecting a 21.43% decline over the last 52 weeks. Investors are likely focused on both the earnings outcome and the company's future guidance.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 7:01 pm

AI

Financial giants have shown a bearish sentiment towards C3.ai (NYSE:AI), with options trading analysis revealing 55% bearish versus 44% bullish trades. The trading activity suggests a price target range of $20.0 to $32.5 for C3.ai. The largest trades include both bearish and bullish positions, with significant activity in puts and calls. C3.ai's current market position shows a trading volume of 3,572,940 and a price decrease of -2.96%, with an earnings announcement expected in 7 days.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 7:01 pm

MGEE

MGE Energy reported Q4 2023 earnings of $0.55 per share with sales of $164.65M, a 13.26% decrease from $189.83M YoY.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 6:51 pm

ATCH

EBS

GBNH

IFF

VTYX

International Flavors & Fragrances Inc. (IFF) shares fell by 8.4% after reporting mixed Q4 results and cutting its dividend by 50%. Other stocks moved significantly in the session, with notable gainers including Greenbrook TMS Inc. (GBNH), Emergent BioSolutions Inc. (EBS), and Ventyx Biosciences, Inc. (VTYX), among others. Losers included AtlasClear Holdings, Inc. (ATCH), Shineco, Inc. (SISI), and Synchronoss Technologies, Inc. (SNCR), with various reasons such as poor financial results, weak guidance, and regulatory issues.

Portfolio Pulse from Avi Kapoor

February 21, 2024 | 6:50 pm

PYPL

SQ

Block Inc (NYSE:SQ) is anticipated to report Q4 earnings with expected revenue of $5.70 billion and EPS of 59 cents, surpassing last year's figures. Analysts have upgraded ratings and price targets, citing potential profitability improvements and the Rule of 40 as key factors. The report follows PayPal's (NASDAQ:PYPL) results, with Block's layoffs and Cash App's regulatory scrutiny also in focus.

Portfolio Pulse from Chris Katje

February 21, 2024 | 6:48 pm

SEDG

SolarEdge Technologies Inc (NASDAQ:SEDG) shares dropped after issuing weak Q1 guidance, with analysts highlighting concerns over structural issues, high fixed costs, and inventory challenges. Price targets were adjusted by several analysts, reflecting a cautious outlook on the company's near-term performance.

Portfolio Pulse from Priya Nigam

February 21, 2024 | 6:46 pm

WGS

GeneDx shares surged following the announcement of their Q4 financial results, which exceeded expectations. Additionally, the company provided positive guidance for the future.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 6:33 pm

LQDA

UTHR

United Therapeutics Corporation (NASDAQ:UTHR) has initiated legal action against the FDA over the approval process of Liquidia Corporation's (NASDAQ:LQDA) drug, claiming the FDA allowed Liquidia to improperly amend an existing new drug application for a second indication for PH-ILD, rather than requiring a new application. United Therapeutics argues this bypasses a potential 30-month stay on approval due to patent infringement litigation. Meanwhile, United Therapeutics reported strong Q4 earnings, with a 25% increase in sales and a significant rise in EPS.

Portfolio Pulse from Vandana Singh

February 21, 2024 | 6:17 pm

DOOR

OC

Stifel analyst Stanley S. Elliott downgraded Masonite International Corporation (NYSE:DOOR) to Hold from Buy, raising the price target to $133 from $119, following mixed Q4 results with revenue and EPS below consensus. The downgrade reflects gains in North America offset by struggles in Europe and Architectural. Additionally, Owens Corning Inc (NYSE:OC) is set to acquire Masonite for $133 per share, a deal expected to close by mid-2024 without anticipated regulatory hurdles. The acquisition aligns with the ongoing consolidation in the building products industry. Masonite's 'Doors That Do More' strategy is expected to drive consistent revenue and margin performance.

Portfolio Pulse from Lekha Gupta

February 21, 2024 | 6:11 pm